Physician profile
Ann Hyatt
NPI 1265691232
$13,447.95
in general payments reported to CMS, 2019-2025
34 companies · $2,662 in 2025
The $2,662 reported for 2025 was more than what 82% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,739 · 2020: $1,165 · 2021: $1,546 · 2022: $2,048 · 2023: $2,011 · 2024: $2,278 · 2025: $2,662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,760 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,760.13 |
| Education | $190.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,545.73 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,986.04 | 2019-2025 | |
| Lilly USA, LLC | $1,155.04 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $986.93 | 2019-2025 | |
| Janssen Biotech, INC. | $977.64 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Incyte Corporation | $806.13 | 2021-2025 | Opzelura |
| Amgen INC. | $701.30 | 2019-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $698.49 | 2019-2025 | Nemluvio, Aklief |
| Ucb, INC. | $690.00 | 2020-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $561.13 | 2019-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $399.59 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $385.57 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $202.60 | 2019-2025 | Siliq, Cabtreo |
| Arcutis Biotherapeutics, INC. | $181.97 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $176.33 | 2022-2025 | Sotyktu |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $148.43 | 2020-2025 | |
| Stemline Therapeutics INC. | $129.40 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.47 | 2023-2024 | Spevigo, Cyltezo |
| Celgene Corporation | $122.64 | 2019 | |
| Mayne Pharma Commercial LLC | $84.45 | 2019-2023 | |
| Leo Pharma INC. | $74.43 | 2019-2024 | Adbry |
| Organon LLC | $45.10 | 2025 | Vtama |
| Prugen, INC. Pharmaceuticals | $39.45 | 2019 | |
| Dermira, INC. | $30.52 | 2020 | |
| Journey Medical Corporation | $29.35 | 2019-2023 | |
| Aclaris Therapeutics, INC. | $29.14 | 2019 | |
| Epi Health, LLC | $28.57 | 2022 | |
| Almirall LLC | $24.22 | 2019 | |
| Vyne Pharmaceuticals INC. | $17.68 | 2020 | |
| Botanix Sb INC | $13.93 | 2025 | Sofdra |
| Lnhc, INC | $13.80 | 2025 | Zelsuvmi |
| Biofrontera INC. | $13.38 | 2019 | |
| Genentech USA, INC. | $11.65 | 2019 | |
| Merck Sharp & Dohme LLC | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Hyatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.